Interestingly, synergistic combinations between HDAC inhibitors and inhibitors of the PI3K/mTOR/Akt pathway have recently been observed in pancreatic cancer, B-cell acute lymphoblastic leukemia and Non-Hodgkin's lymphoma [44–46]. This evidence concerns the gene AKT1 and familial pancreatic carcinoma.